Table 5.
Commonly used risk prediction schemes, annual stroke risk, and antithrombotic recommendations based on guidelines for patients with atrial fibrillation
| CHADS2 score | Stroke risk (%/year) |
CHA2DS2-VASc score |
Stroke risk (%/year) |
Recommended antithrombotic treatment based on CHA2DS2-VASc (Class of recommendation, level of evidence) |
|---|---|---|---|---|
| 0 | 1.9 | 0 | 0 | None (IIb, B) |
| 1 | 2.8 | 1 | 1.3 | None, aspirin, or anticoagulant (IIb, C) |
| 2 | 4.0 | 2 | 2.2 | Anticoagulant (I, A [warfarin], B [dabigatran, rivaroxaban, apixaban] |
| 3 | 5.9 | 3 | 3.2 | |
| 4 | 8.5 | 4 | 4.0 | |
| 5 | 12.5 | 5 | 6.7 | |
| 6 | 18.2 | 6 | 9.8 | |
| 7 | 9.6 | |||
| 8 | 6.7 | |||
| 9 | 15.2 |